Secreted protein acidic and rich in cysteines (SPARC) family includes SPARC,

99
SPARCL1 and SMOC-2, etc. SPARCL1, which is also known as Hevin, SC1 or MAST9, 100 is an extracellular matrix (ECM) glycoprotein, whose gene is located in 4q22 (5, 6).
101
SPARCL1 was first isolated from a human high endothelial venules cDNA library and is 102 involved in many physiological functions, such as cell adhesion (7, 8), cell proliferation 103 (7), central nervous system development (9) and B-lymphocyte maturation (10).
104
SPARCL1 is widely expressed in normal tissues such as brain, heart, lung, muscle, 105 colon and kidney (5, 6, 11-13). In contrast, its full-length expression was strongly 106 down-regulated in several carcinomas such as metastatic prostate adenocarcinoma and 107 non-small cell lung cancer (5, 8, 14-16). The down-regulation of SPARCL1 mRNA in 108 colorectal carcinomas was confirmed by northern blotting (9) and oligonucleotide array 7 progressing from Dukes Stage B to D. However, their data showed that expression of 114 SPARCL1 led to poor survival in CRCs (19). Therefore, the prognostic value of 115 SPARCL1 needs to be further investigated at multiple centers with larger population. 116 Meanwhile, it was necessary to further explore the malignancy-suppressing ability of 117 SPARCL1 to clarify the mechanism(s) . 118 In this study, we investigated whether the expression of SPARCL1 in colon cell 119 lines reduces cell proliferation, invasion or metastasis in an in vitro setting and in 120 mouse xenograft model. In addition, we explored the biological role of SPARCL1 121 protein in anchorage-independent growth, migration and differentiation of cells. Fig 1) . Moreover, the signal of recombinant SPARCL1 protein and 153 endogenous SPARCL1 (75 KDa and 130 KDa) could be specifically blocked by 154 recombinant SPARCL1 full length peptide (Supplemental Fig. 1 vector controls after normalizing to β-actin (Fig. 1A，upper panels) . The secretion of 303 SPARCL1 protein was also elevated in the culture medium of SPARCL1-transfectant 304 cells (Fig. 1A，lower panels) . In the cell proliferation study performed using cell 305 counting method, the growth of SPARCL1 transfectants decreased significantly both in 306 RKO (day 6, P = 0.03) and SW620 (day 6, P = 0.04) cells in comparison to 307 corresponding vector control (Supplemental Fig. 3B upper panels) . Additionally, 308 when the MTS method was used to assess cell proliferation, it showed that the growth 309 of SPARCL1 transfectants decreased both in RKO (day 5, P > 0.05) and SW620 (day 5, 310 P > 0.05) cells compare to the vector control (Supplemental Fig. 3B lower panels) .
311
The ability of anchorage-independent growth also reflects the potential of cancer 312 metastasis.
Consistently, the colony formation of RKO-SPARCL1 and 313 SW620-SPARCL1 was dropped by 54-62% (P < 0.01) and 19-48% (P = 0.03),
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Research. 
respectively, which indicated that anchorage-dependent growth was retarded in 315 SPARCL1 expressing cells (Fig. 1B) . Recombinant SPARCL1 peptide significantly 316 reduced the colony formation by RKO cells (P < 0.01), as well as SW620 cells (P < 317 0.01) (Supplemental Fig. 3C ).
318
The abilities to migrate and invade were regarded as the main malignant 319 phenotype and prerequisite of metastasis for cancer cells. In wound-healing assay, it 320 was shown that the SPARCL1 transfectants significantly reduced the migration ability (Fig. 1D , P = 0.01).
325
The invasion ability was significantly enhanced when we applied IL-8 as 326 chemoatractant in both RKO and SW620 cells (P < 0.01). While, it was significantly 327 reduced by the recombinant SPARCL1 peptide (P < 0.01) (Supplemental Fig. 3E ). (Table 2) . 385 Above findings suggested that the SPARCL1 expression correlated with greater 386 differentiation, and negatively associated with lymph node involvement and distant 387 metastasis, which implies that SPARCL1 may function as a tumor suppressor in CRCs. (Fig. 3C) . This finding also confirmed in ZJU 400 set (HR = 0.57, 95% CI 0.39-0.84) (Fig. 3D) . The HR's pattern of other co-factors Fig. 6A right panel) . 415 However, SPARCL1 seems not to impact the overall survival of rectal cancer patients in 416 either COH set or ZJU set (Supplemental Table 3 ). Fig. 6B left panel) . It was consistent with results yielded from ZJU set 422 (Log-rank P = 0.023) (Supplemental Fig. 6B, right panel) . Meanwhile, SPARCL1 423 predicting better survival was also seen in CRC patients with stage III-IV 424 (Supplemental Fig. 6C ).
Multivariate analysis also displayed similar results
425
(Supplemental Table 3 (Fig 4A: a-c) . Meanwhile, SPARCL1 steadily increased 436 as with poor, moderate and well differentiation of CRCs (Fig 4A: d-f) . The lumen-like (Fig. 4B) . 440 Correspondingly, recombinant SPARCL1 peptide also could promote the lumen-like 441 formation (Fig. 4) . The E-cadherin, N-cadherin and Vimentin were regarding as the 442 MET related genes. It was indicated that the mRNA expression level of E-cadherin 443 was significantly up-regulated on RKO-SPARCL1 and SW620-SPARCL1 transfectants, 444 and N-cadherin and Vimentin were significantly down-regulated (Fig. 4C) . The
445
Western blot analysis further confirmed that increase of that E-cadherin and decrease of 446 N-cadherin and Vimentin could be seen in SPARCL1 expression RKO and SW620 447 transfectants (Fig. 4D) . Meanwhile, qRT-PCR analysis also demonstrated that the 
Discussion
454
In this study, we demonstrated that SPARCL1 suppresses the proliferation, 455 migration, invasion and anchorage-independent growth of colon cancer cells (Fig. 1) . 456 The expression of SPARCL1 also induces the differentiation of colon cancer cells (Fig.   457   4) . The results are consistent with previously conducted in vitro studies (8, 22) . 458 Here, we further report the in vivo findings obtained using xenograft animal models. 459 In the subcutaneous xenograft mouse model, the expression of SPARCL1 retarded 460 tumor growth, which points to its anti-proliferation potential (Supplemental Fig. 4) . 461 We utilized an intra-splenic injection mouse model mimicking liver metastasis of CRC 462 at the later stages. This was based on the anatomy assumption that colon cancer cells 463 migrate mostly through vena porta hepatic (23). The liver-metasis animal model 464 indicated that SPARCL1 significantly reduces the liver metastasis by RKO cells (Fig. 2) . 465 These in vitro and in vivo studies validate that the expression of SPARCL1 has potential 466 malignancy-suppressing ability in colon cancer cells. 467 In the outcomes study, expression of SPARCL1 was significantly related to better 468 survival of CRCs in two sets of patients with different socio-economic backgrounds. 469 The SPARCL1 expression was associated with well-differentiation in patients from 470 COH set (P = 0.06) and ZJU set (P < 0.01), which was consistent with the in vitro (Fig 3B, Supplemental Fig. 6B and 6C right panel) The opposing results by two research teams may be due to different antibodies that 484 were used for IHC. We tested the commercial antibody (R&D) and found many 485 non-specific signals on Western blot analysis ( Supplemental Fig 1) . Therefore, we No. C11 were barely seen on Western blot analysis ( Supplemental Fig 1) . Meanwhile, 488 the intensity of specific signal detected by our antibody correlates with the SPARCL1 489 mRNA level (Fig 1A) . The signal was blocked by SPARCL1 peptide (Supplemental (Supplemental Fig 3F) 
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The GAPDH was used as a loading control. 
